Key result
Moxonidine treatment for 12 weeks significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR, and albumin excretion, and increased serum adiponectin.
Why the study?
Does moxonidine improve adiponectin levels and metabolic parameters in non-diabetic women with essential hypertension?
Does moxonidine improve adiponectin levels and metabolic parameters in non-diabetic women with essential hypertension?
Moxonidine improves insulin resistance and increases adiponectin levels in non-diabetic hypertensive women, suggesting metabolic benefits beyond blood pressure lowering.
Answers are grounded in this paper and cite their sources.
May support metabolic benefits beyond BP lowering in non-diabetic hypertensive women; leaves open confirmation in randomized trials.
We examined whether moxonidine influences lipid profile, insulin resistance, adiponectin levels, renal function and microalbuminuria in women with essential hypertension in a study of 55 non-diabetic hypertensive patients and 53 normotensive women. Hypertensive patients received moxonidine for 12 weeks. At baseline the hypertensive group had significantly higher mean blood pressure, low-density lipoprotein cholesterol, triglycerides, total cholesterol, fasting glucose, urinary albumin excretion and homeostasis model assessment of insulin resistance (HOMA-IR), together with significantly lower mean high-density lipoprotein cholesterol, creatinine clearance and serum adiponectin than the normotensive group. Moxonidine significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR and albumin excretion, but significantly increased serum adiponectin. The change in adiponectin level was negatively correlated with the change in HOMA-IR. Moxonidine treatment may improve unfavourable metabolic status related to insulin resistance by increasing adiponectin levels in patients with essential hypertension. Since it can improve adiponectin levels, it may be used in the antihypertensive treatment of patients at high risk of diabetes and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Ebinç et al. (2008) studied Essential hypertension (n=108). Moxonidine vs. Normotensive women (baseline) / Pre-treatment baseline was evaluated on Lipid profile, insulin resistance, adiponectin levels, renal function and microalbuminuria. Moxonidine treatment for 12 weeks significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR, and albumin excretion, and increased serum adiponectin.
Synapse has enriched 10 related papers. Consider them for comparative context: